Navigation Links
Actos Bladder Cancer Lawsuit News: Bernstein Liebhard LLP Comments on India Regulatory Agency Decision to Ban Actos
Date:7/13/2013

New York, New York (PRWEB) July 13, 2013

As Actos bladder cancer lawsuit claims continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that India’s drug regulator has decided to ban Actos. According to a June 27th report from India Today, the Ministry of Health and Family Welfare enacted a ban on Actos and other forms of poglitazone under the country’s Drugs and Cosmetic Act, citing its association with bladder cancer and congestive heart failure.*

“We have heard from numerous individuals seeking to file Actos lawsuits that allege the drug caused their bladder cancer. Considering recent research pointing to a link between Actos and the disease, it is not surprising that India took this step,” says Bernstein Liebhard LLP, nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to patients who developed the disease after using the medication for an extended period of time.

Actos Lawsuits
Actos is approved to lower blood sugar in patients with type 2 diabetes. In June 2011, the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year or more had been linked to the development of bladder cancer.** According to Bloomberg.com, Actos was also pulled from the market in Germany and France that month because of its association with bladder cancer.***

According to an update issued by the U.S. Judicial Panel on Multidistrict Litigation on July 10th, more than 2,400 Actos lawsuits are pending in a consolidated proceeding underway in U.S. District Court, Western District of Louisiana. All of the claims filed in the litigation allege long-term use of Actos may cause or worsen bladder cancer. Plaintiffs further allege that Takeda Pharmaceuticals failed to provide adequate warnings to doctors and patients regarding the drug’s association with an increased risk of bladder cancer. The first trial in the federal Actos litigation is scheduled to begin on January 27, 2014. (In re: Actos Product Liability Litigation, MDL No. 2299)

Additional Actos bladder cancer lawsuits have also been filed in various federal courts around the country. In April, the nation’s first trial involving Actos bladder cancer allegations ended with a Los Angeles Superior Court jury awarding $6.5 million to a plaintiff who was diagnosed with the disease after taking Actos for four years. However, the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

Long-term users of Actos who have been diagnosed with bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos bladder cancer lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

*indiatoday.intoday.in/story/govt-bans-drugs-anti-diabetes-analgin-pioglitazone-anti-depressant-deanxit-drugs-and-cosmetic-act/1/285575.html
**fda.gov/drugs/drugsafety/ucm259150.htm, FDA, June 15, 2011
***bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html, Bloomberg, March 5, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
###

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/Actos-lawsuit/Actos-bladder-cancer/prweb10925240.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... CURE Media Group, the nation’s leading digital and print media ... Lung Cancer in efforts to combat lung cancer, announced CURE Media Group President Michael ... Media Group is honored to team up with Upstage Lung Cancer in order to ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental Laboratories ... and patients about the safety issues related to dental restorations. According to the American ... projected to reach $6.4 billion in 2018 with more than 30 million Americans missing ...
(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016 Bodycad announced it has been ... accuracy, reproducibility and speed for 3D constructs via ... bone orthopaedic applications. These patents are critical to ... restorations based on each patient,s distinct anatomy. ... harnesses the world,s first suite of orthopaedic CAD/CAM ...
(Date:12/8/2016)... 2016  Pennsylvania Physician General Dr. Rachel ... Programs Gary Tennis released safe prescribing ... benzodiazepines, developed with the help of a task ... are frequently prescribed for anxiety or insomnia," said ... opioid pain medications, benzodiazepines pose a significant risk ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: